PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/00, 31/165, 31/42, 31/435, 31/44, 31/445

A1

(11) International Publication Number: **WO 97/02813**

(43) International Publication Date: 30 January 1997 (30.01.97)

(21) International Application Number: PCT/EP96/03018

(22) International Filing Date: 10 July 1996 (10.07.96)

(30) Priority Data:
195 25 598.4 13 July 1995 (13.07.95) DE

(71) Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; D-Berlin (DE).

(72) Inventor: LANCEL, Marike; Kraepelinstrasse 4a, D-80804 Munich (DE).

(74) Agent: VOSSIUS & PARTNER; P.O. Box 86 07 67, D-81634 Munich (DE).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: NON-ALLOSTERIC $GABA_A$ AGONISTS FOR TREATING SLEEP DISORDERS

(57) Abstract

The invention relates to a method of treating sleep disorders in a patient in need thereof comprising the administration of a hypnotically effective amount of a non-allosteric $GABA_A$ agonist.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	**GB**	United Kingdom	**MW**	Malawi
AT	Austria	**GE**	Georgia	**MX**	Mexico
AU	Australia	**GN**	Guinea	**NE**	Niger
BB	Barbados	**GR**	Greece	**NL**	Netherlands
BE	Belgium	**HU**	Hungary	**NO**	Norway
BF	Burkina Faso	**IE**	Ireland	**NZ**	New Zealand
BG	Bulgaria	**IT**	Italy	**PL**	Poland
BJ	Benin	**JP**	Japan	**PT**	Portugal
BR	Brazil	**KE**	Kenya	**RO**	Romania
BY	Belarus	**KG**	Kyrgystan	**RU**	Russian Federation
CA	Canada	**KP**	Democratic People's Republic of Korea	**SD**	Sudan
CF	Central African Republic			**SE**	Sweden
CG	Congo	**KR**	Republic of Korea	**SG**	Singapore
CH	Switzerland	**KZ**	Kazakhstan	**SI**	Slovenia
CI	Côte d'Ivoire	**LI**	Liechtenstein	**SK**	Slovakia
CM	Cameroon	**LK**	Sri Lanka	**SN**	Senegal
CN	China	**LR**	Liberia	**SZ**	Swaziland
CS	Czechoslovakia	**LT**	Lithuania	**TD**	Chad
CZ	Czech Republic	**LU**	Luxembourg	**TG**	Togo
DE	Germany	**LV**	Latvia	**TJ**	Tajikistan
DK	Denmark	**MC**	Monaco	**TT**	Trinidad and Tobago
EE	Estonia	**MD**	Republic of Moldova	**UA**	Ukraine
ES	Spain	**MG**	Madagascar	**UG**	Uganda
FI	Finland	**ML**	Mali	**US**	United States of America
FR	France	**MN**	Mongolia	**UZ**	Uzbekistan
GA	Gabon	**MR**	Mauritania	**VN**	Viet Nam

Non-allosteric $GABA_A$ agonists for treating sleep disorders

Field of the invention

This invention relates to the use of non-allosteric $GABA_A$ agonists for treating sleep disorders.

Background

The hypnotics most frequently prescribed for the treatment of sleep disorders are classic benzodiazepines as well as compounds like zolpidem and zopiclone. These compounds shorten sleep latency and increase total sleep time. The pharmacological effect of these compounds is assumed to be due to a modulation of the $GABA_A$ receptor (γ-aminobutyric-$acid_A$ receptor); however they neither increase neuronal release of GABA nor block the reuptake of released GABA. They have no direct $GABA_A$ agonistic effect either. On the contrary, they react with specific binding sites which belong to a complex consisting of GABA receptors, various distinct modulatory receptors among others for benzodiazepines and a chloride ion channel, and thus cause the $GABA_A$ receptor to undergo an allosteric change. This allosteric change influences the efficacy of GABA in promoting chloride channel opening.

However, such $GABA_A$ receptor modulators exhibit considerable side effects. Especially with the use of benzodiazepines, tolerance and dependency develop rapidly, and rebound insomnia, which will manifest itself by restlessness and somnipathy, emerges upon withdrawal.

Furthermore, the quality of sleep induced by said $GABA_A$ receptor modulators is unphysiological. REMS (= rapid eye movement sleep) as well as the deeper phases of nonREMS (slow-wave sleep) are disturbed.

For example, benzodiazepines and all other common hypnotics cause the following sleep profile.

1) they inhibit REMS

2) they promote nonREMS

3) they decrease delta activity (0.5-4 Hz) in the EEG within nonREMS by

   a) reducing the rate of rise of delta activity at the beginning the nonREMS episodes, and

   b) reducing the maximum delta activity during nonREMS episodes.

In one of two studies, Mendelson et al. (Life Sci 47, (1990) 99, 101; Life Sci 53 (1993) 81-87) found that muscimol, a GABA analogue and selective $GABA_A$ agonist, does cause a slight reduction of sleep latency but does not influence sleep as such. This finding resulted in the common opinion that non-benzodiazepoid $GABA_A$ agonists are devoid of any clinical beneficial effects on sleep disorders. Furthermore, it is generally accepted in the field that if a substance has a sedative side effect or causes a slight reduction in sleep latency, this will not justify its classification as a hypnotic.

In Pharmacol. Biochem. and Behaviour (1993), vol 45, pp 881-887, Suzuki et al investigated the effect of 3 mg/kg muscimol IP in different inbred strains of rats (Fischer 344, and Lewis) by measuring the loss and duration of the righting reflex. The authors of this document equate the duration of loss of the righting reflex to an hypnotic effect (sleep time). However, it is well established that the behavioral parameter "righting reflex" bears no relationship with sleep. In the rat, very high doses of

muscimol, such as 3 mg/kg, are known to evoke absence epilepsy. It is in fact highly likely that the perceived sedation ("loss of righting reflex") represents a pathological state of an epileptiform nature (see "Hypersynchronisation and Sedation Produced by GABA-Transaminase Inhibitors and picrotoxin: Does GABA Participate in Sleep Control?", Waking and Sleeping (1979), 3: 245-254).

In US-A-5,185,446 cycloalkylinidazo pyrimidine derivatives are disclosed which are described as being selective agonists, antagonists or inverse agonists for $GABA_a$ brain receptors and may be used in the diagnosis and treatment of anxiety, sleep and other disorders. All of these compounds are, however, allosteric $GABA_a$-receptor modulators. In Pharmacol. Biochem. and Behaviour (1988), vol 29, pp 781-783, the hypnotic effects of the allosteric $GABA_a$-receptor modulators are described.

The object underlying the present invention is to provide an effective hypnotic which has no significant side effects and causes a sleep profile essentially corresponding to physiological sleep.

Summary of the invention

The present invention provides a method of treating sleep disorders in a patient in need thereof comprising the administration of a hypnotically effective amount of a non-allosteric $GABA_A$ agonist.

Detailed description of the invention

The present invention is based on the unexpected finding that the $GABA_A$ agonists muscimol and THIP (4,5,6,7-tetrahydroisoxazolo(5,4-C)pyridin-3-ol) have very advantageous effects on sleep. The activity profiles of

muscimol- and THIP-induced sleep can be summarized as follows:

1) The total duration of nonREMS and REMS is increased after muscimol and THIP increases nonREMS.

2) Prolongation of nonREMS episodes as well as REMS episodes, which supports sleep continuity.

3) The EEG-delta activity within nonREMS is enhanced; this is achieved by

   a) increasing the rise rate of delta activity at the beginning of each nonREMS episode,

   b) increasing the maximum delta activity during the nonREMS episodes, and

   c) prolonging the nonREMS episodes (see 2).

All above-summarized changes correspond to the sleep profile observed with a physiological increase in sleep need, for instance, after an extended period of wakefulness. This shows that a non-allosteric $GABA_A$ agonist, unlike benzodiadepines and all other common hypnotics, can induce sleep having the characteristics of natural sleep.

Results similar to those observed using the full $GABA_A$ agonist muscimol and the partial $GABA_A$ agonist THIP could also be achieved by using other non-allosteric $GABA_A$ agonists, GABA transaminase inhibitors, such as vigabatrin, and GABA uptake inhibitors, such as tiagabine. It was thus found that the pharmacological stimulation of the GABA binding site of the $GABA_A$ receptor, either directly by administering a $GABA_A$ agonist or indirectly by increasing the endogenous GABA concentration by way of a GABA prodrug, GABA uptake inhibitor or GABA transaminase inhibitor, can be

of considerable therapeutic advantage in the treatment of sleep disorders.

Thus, the invention relates to a method of treating sleep disorders in a patient in need thereof comprising the administration of a substance which either directly or indirectly stimulates the GABA binding site of the $GABA_A$ receptor in an hypnotically effective amount. Substances which stimulate the GABA binding site of the $GABA_A$ receptor are referred to herein as non-allosteric $GABA_A$ agonists.

Examples of such compounds include in particular:
$GABA_A$ agonists which exert a direct effect on $GABA_A$ receptors, such as muscimol, thiomuscimol, THIP, thioTHIP, isoguvacine,
GABA prodrugs, such as progabide,
GABA uptake inhibitors, such as tiagabine and
GABA transaminase inhibitors, such as vigabatrin.

Especially preferred is the use of partial agonists since they do not result in a rapid desensitisation of the $GABA_A$ receptor.

Due to their pharmacological properties, the above-mentioned substances having a direct or indirect non-allosteric agonistic effect on the $GABA_A$ receptor are therapeutically beneficial in a broad range of sleep disorders, including difficulties in falling asleep, frequent nocturnal arousals, early morning awakening and/or a dissatisfaction with the intensity of sleep.

The compounds are particularly suitable for the treatment of elderly patients.

In effecting treatment of a patient afflicted with a sleep disorder in accordance with the method of the invention, the non-allosteric $GABA_A$ agonist can be formulated in a manner

well-known in the art using common pharmaceutical adjuvants and optionally in combination with other active substances to form common galenic preparations, such as tablets, coated tablets, capsules, powders, suspensions, injectable solutions or suppositories.

In accordance with the subject matter of the invention, the compounds can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, the compounds can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, topically, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances.

The compounds can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and chemical properties of the compound selected, the chosen route of administration, and standard pharmaceutical practice. The compounds of the invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.

The dose to be administered depends on the patient's age and weight as well as the degree and nature of sleep disorder. Preferably, the non-allosteric $GABA_A$ agonists used according to this invention are administered in a dose of 5 mg to 50 mg per day. The administration may be intravenous or intramuscular. However, oral administration is preferred.

As used herein, the term "hypnotically effective amount" means an amount sufficient to reduce sleep latency, prolong REMS, prolong nonREMS, prolong total sleep or enhance EEG-delta activity during sleep.

The following examples serve to explain the invention in more detail. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way.

Example 1

After intraperitoneal administration of placebo (pyrogen-free saline) or muscimol (0,2 and 0,4 mg/kg), the EEG and EMG as well as the brain temperature of adult rats were continuously recorded.

Muscimol resulted in a dose-dependent increase of nonREMS and REMS and a prolongation of REMS and nonREMS episodes. From the analysis of the nonREMS episodes in the EEG spectrum, it became evident that muscimol, in particular in higher doses, increases the EEG activity in all frequency bands, most potently, however, at lower frequencies (0.5 to 4 Hz), thought to reflect sleep intensity.

Example 2

After intraperitoneal administration of Placebo (pyrogen-free saline) or THIP (2 and 4 mg/kg), the EEG and EMG as well as the brain temperature of adult rats were continuously recorded.

THIP dose-dependently increased the total amount of nonREMS and lengthened the duration of the nonREMS and REMS episodes. The higher dose of THIP elevated delta activity

within nonREMS, generally believed to reflect an increase in nonREMS intensity.

Corresponding results were also obtained using vigabatrin.

Example 3

In a double blind, placebo controlled study the effects of 20 mg THIP administered in gelatine capsules at 22:30 h on sleep in 10 young, healthy male subjects was investigated. The subjects went to bed at 23:00 h and time in bed was not restricted. Compared to the placebo condition, THIP significantly increased sleep efficiency and enhanced total time spent in slow wave sleep (stages 3 and 4) by about 30 minutes. Spectral analysis of the EEG within nonREMS (stages 2, 3 and 4) showed that THIP significantly elevated delta activity (cumulative power in the frequency bins between 0.78 and 4.30 Hz) and depressed sigma activity (cumulative power in the frequency bins between 12.50 and 14.83 Hz, the spindle frequency bands). Analysis of the development of delta and sigma activity over the first 30 minutes of the nonREMS episodes revealed that during THIP delta activity increased more rapidly and reached higher levels, while sigma activity remained below placebo values. These effects are highly similar to those induced by sleep deprivation in humans.

The effects of THIP on sleep in young human subjects, with no sleep disturbances, confirm and extend the findings of $GABA_A$ agonists in rats and show that THIP, similar to sleep deprivation and in contrast to existing hypnotics, promotes deep nonREMS, without suppressing REMS.

Example 4

Coated tablets:

1 tablet contains:

THIP	40.00 mg
microcristalline cellulose	100.00 mg
lactose	80.00 mg
colloidal silicic acid	25.00 mg
talcum (in the core)	4.50 mg
magnesium stearate	0.50 mg
hydroxypropylmethylcellulose	12.00 mg
ironoxide pigment	0.10 mg
talcum (in the coating)	0.50 mg
weight of one coated tablet	approx. 262.60 mg

We claim:

1. A pharmaceutical composition for treating a sleep disorder comprising a non-allosteric $GABA_A$ agonist.

2. The pharmaceutical composition according to claim 1, wherein said non-allosteric $GABA_A$ agonist exerts a direct effect on said $GABA_A$ receptor.

3. The pharmaceutical composition according to claim 2, wherein said $GABA_A$ agonist is a partial agonist.

4. The pharmaceutical composition according to claim 1, wherein said $GAGA_A$ agonist is an indirect GABA agonist.

5. The pharmaceutical composition according to claim 4, wherein said non-allosteric $GABA_A$ agonist is a GABA uptake inhibitor.

6. The pharmaceutical composition according to claim 4, wherein said non-allosteric $GABA_A$ agonist is a GABA transaminase inhibitor.

7. The pharmaceutical composition according to claim 4, wherein said non-allosteric $GABA_A$ agonist is a GABA prodrug.

8. The pharmaceutical composition according to claim 4, wherein said non-allosteric $GABA_A$ agonist is muscimol, thiomuscimol, THIP, thioTHIP or isoguvacine.

9. The pharmaceutical composition according to claim 7, wherein said non-allosteric $GABA_A$ agonist is progabide.

10. The pharmaceutical composition according to claim 5, wherein said non-allosteric $GABA_A$ agonist is tiagabine.

11. The pharmaceutical composition according to claim 1, wherein said patient is elderly.

12. The pharmaceutical composition according to claim 1, wherein said sleep disorder is difficulty in falling asleep.

13. The pharmaceutical composition according to claim 1, wherein said sleep disorder is frequent nocturnal arousal.

14. The pharmaceutical composition according to claim 1, wherein the amount of agonist administered is 5 to 50 mg per day.

15. Use of a non-allosteric $GABA_A$ agonist for the preparation of a pharmaceutical composition as defined in any one of claims 1-14.

16. A method for treating a sleep disorder in a patient in need thereof comprising administering to said patient a hypnotically effective amount of a non-allosteric $GABA_A$ agonist.

INTERNATIONAL SEARCH REPORT

In' ational Application No
PCT/EP 96/03018

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/00 A61K31/165 A61K31/42 A61K31/435 A61K31/44 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,5 192 550 (EDGREN ET AL.) 9 March 1993 see the whole document ---	1,7,9
X	US,A,5 354 760 (PETERSEN ET AL.) 11 October 1994 see the whole document ---	1,5,10
X	WO,A,93 18762 (ALLERGAN) 30 September 1993 see claims --- -/--	1,4,8

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 November 1996	11. 12. 96

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Klaver, T

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	NEUROPSYCHOPHARMACOLOGY, vol. 15, no. 1, 1996, pages 63-74, XP000609465 M. LANCEL ET AL.: "Role of GABAa receptors in sleep regulation: differential effects of muscimol and midazolam on sleep in rats." see the whole document ---	1,4,8, 15,16
A	CRIT. REV. NEUROBIOL., vol. 6, no. 4, 1992, pages 221-232, XP000609466 W.B. MENDELSON: "Neuropharmacology of sleep induction by benzodiazepines." -----	

INTERNATIONAL SEARCH REPORT

Inte tional application No.
PCT/EP 96/03018

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although the claims are directed to a method of treatment /diagnosis of the human or animal body, the search has been carried out, based on the alleged effects of the compound/composition (rule 39.1(iv)PCT)

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int tional Application No
PCT/EP 96/03018

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-5192550	09-03-93	US-A-	5190763	02-03-93
		US-A-	5221536	22-06-93
		AT-T-	113203	15-11-94
		AU-B-	641770	30-09-93
		AU-A-	7854391	27-11-91
		CA-A-	2041579	08-11-91
		DE-D-	69104830	01-12-94
		DE-T-	69104830	02-03-95
		EP-A-	0527835	24-02-93
		ES-T-	2067231	16-03-95
		IE-B-	62397	25-01-95
		NZ-A-	238011	21-12-95
		NZ-A-	248491	21-12-95
		WO-A-	9116885	14-11-91
US-A-5354760	11-10-94	AU-B-	661483	27-07-95
		AU-A-	1641592	02-11-92
		CA-A-	2107223	03-10-92
		WO-A-	9217473	15-10-92
		EP-A-	0579681	26-01-94
		IL-A-	101358	04-08-96
		JP-T-	6506209	14-07-94
		NZ-A-	242191	26-07-94
WO-A-9318762	30-09-93	AU-A-	3810893	21-10-93
		CA-A-	2132102	30-09-93
		EP-A-	0630240	28-12-94
		JP-T-	7505156	08-06-95